Our business idea is to help people with chronic conditions and illnesses by using a patented treatment method that is neither surgical nor drug-based. The treatment is called Ozilia® and is based on the Kinetic Oscillation Stimulation technology.
Ozilia® is a product system for neurostimulation therapy with long-term effects, which modulates the autonomic nervous system functions. The treatment is CE-marked, has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East.
We sell our product system and our treatments through distributors to clinics and hospitals, who in turn treat the patients.
Today, the company has three employees, supported by a handful of expert consultants with extensive overall experience in medical technology product development, international market establishment, and clinical study activities. The business is entirely focused on sales in a few selected markets and the implementation of the two ongoing studies.
Chordate Medical AB, the Group’s operating company, is a wholly owned subsidiary of Chordate Medical Holding AB (Publ), was listed on Nordic Growth Market-SME on March 8, 2017 and is since February 15, 2022, traded on Nasdaq First North Growth Market.
The company is based in Kista, outside Stockholm.
The highly respected scientific journal Neurology has published the scientific article on Chordate Medical's registration study PM007 on preventive neurostimulation treatment for chronic migraine.
The publication confirms that the medical effect of the Ozilia treatment is on par with conventional drug-based alternatives for the preventive treatment of chronic migraine.
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the Ozilia® Migraine treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia®, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH).
The company’s Certified Adviser on Nasdaq First North Growth Market Stockholm is Bergs Securities AB.
Färögatan 33
SE-164 51 Kista
Sweden
For visits: floor B31
Delivery: Hanstavägen 31, 164 53 Kista
